Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board
11 July 2018 - 8:00PM
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that
Shawn Cline Tomasello has joined its Board of Directors. With more
than 30 years’ experience in the pharmaceutical and biotech
industries, Ms Tomasello brings substantial commercial and
transactional experience to the Mesoblast board.
Since 2015, Ms Tomasello has been Chief
Commercial Officer at leading immuno-oncology cell therapy company
Kite Pharma, where she played a pivotal role in the company’s
acquisition in 2017 by Gilead Sciences for $11.9 billion. Prior to
this she served as Chief Commercial Officer at Pharmacyclics, Inc.,
which was acquired in 2015 by AbbVie, Inc. for $21 billion. Ms
Tomasello previously was President of the Americas, Hematology and
Oncology at Celgene Corporation where she managed over $4 billion
in product revenues, and was instrumental in various global
expansion and acquisition strategies. She has also held senior
positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals
and Procter & Gamble. Ms Tomasello currently serves on the
Board of Directors of Centrexion Therapeutics, Oxford
BioTherapeutics and Diplomat Rx.
Commenting on her appointment, Ms Tomasello said, “I have been
extremely impressed by Mesoblast’s technology and the rigor with
which the company has moved its programs towards commercialization.
Mesoblast’s cellular medicines have the potential to make a
substantial impact on the treatment of life-threatening conditions
in a way not possible with traditional approaches. I look forward
to making an important contribution to Mesoblast’s commercial and
strategic objectives.”
Mesoblast Chief Executive Dr Silviu Itescu stated: “Shawn’s
substantial commercial experience will be invaluable to the
Mesoblast product launch team as we transition to a
commercial-stage company. As important, Shawn’s unparalleled
transactional experience will greatly strengthen our ability to
execute on our strategic objectives.”
Ignite Partners advised Mesoblast on the appointment of Ms
Tomasello.
About Mesoblast Mesoblast Limited
(Nasdaq:MESO) (ASX:MSB) is a world leader in developing allogeneic
(off-the-shelf) cellular medicines. The Company has leveraged its
proprietary technology platform to establish a broad portfolio of
late-stage product candidates with three product candidates in
Phase 3 trials – acute graft versus host disease, chronic heart
failure and chronic low back pain due to degenerative disc disease.
Through a proprietary process, Mesoblast selects rare mesenchymal
lineage precursor and stem cells from the bone marrow of healthy
adults and creates master cell banks, which can be industrially
expanded to produce thousands of doses from each donor that meet
stringent release criteria, have lot to lot consistency, and can be
used off-the-shelf without the need for tissue matching. Mesoblast
has facilities in Melbourne, New York, Singapore and Texas and is
listed on the Australian Securities Exchange (MSB) and on the
Nasdaq (MESO). www.mesoblast.com
Forward-Looking StatementsThis announcement
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. We make such forward-looking statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Forward-looking
statements should not be read as a guarantee of future performance
or results, and actual results may differ from the results
anticipated in these forward-looking statements, and the
differences may be material and adverse. Forward-looking statements
include, but are not limited to, statements about the timing,
progress and results of Mesoblast’s preclinical and clinical
studies; Mesoblast’s ability to advance product candidates into,
enroll and successfully complete, clinical studies; the timing or
likelihood of regulatory filings and approvals; and the pricing and
reimbursement of Mesoblast’s product candidates, if approved. You
should read this press release together with our risk factors, in
our most recently filed reports with the SEC or on our website.
Uncertainties and risks that may cause Mesoblast’s actual results,
performance or achievements to be materially different from those
which may be expressed or implied by such statements, and
accordingly, you should not place undue reliance on these
forward-looking statements. We do not undertake any obligations to
publicly update or revise any forward-looking statements, whether
as a result of new information, future developments or
otherwise.
For further information, please contact:
Julie Meldrum
Corporate Communications
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Schond GreenwayInvestor RelationsT: +1 212 880
2060E: schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2023 to Apr 2024